MXPA01008056A - Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada. - Google Patents

Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada.

Info

Publication number
MXPA01008056A
MXPA01008056A MXPA01008056A MXPA01008056A MXPA01008056A MX PA01008056 A MXPA01008056 A MX PA01008056A MX PA01008056 A MXPA01008056 A MX PA01008056A MX PA01008056 A MXPA01008056 A MX PA01008056A MX PA01008056 A MXPA01008056 A MX PA01008056A
Authority
MX
Mexico
Prior art keywords
crystalline form
dissolution rate
exhibiting enhanced
enhanced dissolution
form exhibiting
Prior art date
Application number
MXPA01008056A
Other languages
English (en)
Spanish (es)
Inventor
Barton Kathleen
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA01008056A publication Critical patent/MXPA01008056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA01008056A 1999-12-08 2000-12-04 Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada. MXPA01008056A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16955699P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16969099P 1999-12-08 1999-12-08
US16968299P 1999-12-08 1999-12-08
PCT/US2000/032416 WO2001042272A2 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate

Publications (1)

Publication Number Publication Date
MXPA01008056A true MXPA01008056A (es) 2003-07-21

Family

ID=27558585

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01008056A MXPA01008056A (es) 1999-12-08 2000-12-04 Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada.

Country Status (17)

Country Link
EP (1) EP1177204A2 (https=)
JP (1) JP2003516414A (https=)
KR (1) KR100607923B1 (https=)
CN (2) CN1152886C (https=)
AU (1) AU784946B2 (https=)
BR (1) BR0008057A (https=)
CA (1) CA2362669A1 (https=)
CO (1) CO5280211A1 (https=)
EA (1) EA007934B1 (https=)
HU (1) HUP0203032A3 (https=)
IL (3) IL144764A0 (https=)
MX (1) MXPA01008056A (https=)
MY (1) MY131878A (https=)
NO (1) NO20013856L (https=)
NZ (2) NZ530028A (https=)
PE (1) PE20010917A1 (https=)
WO (1) WO2001042272A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072797A1 (en) * 2002-03-20 2004-04-15 Pornanong Aramwit Storage stable eplerenone formulation
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (en) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
WO2023204729A1 (ru) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции
CN120754115A (zh) * 2025-05-23 2025-10-10 远大医药（中国）有限公司 一种含依普利酮组合物及其药物制剂、制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
PT944644E (pt) * 1996-12-11 2003-02-28 Searle & Co Processos para a preparacao de esteroides 9,11-epoxi e intermediarios uteis para esse efeito
IL145237A0 (en) * 1999-03-05 2002-06-30 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Also Published As

Publication number Publication date
WO2001042272A3 (en) 2001-11-29
NZ530028A (en) 2005-08-26
WO2001042272A9 (en) 2002-12-12
HUP0203032A2 (hu) 2002-12-28
NO20013856D0 (no) 2001-08-08
IL144764A0 (en) 2002-06-30
AU2049201A (en) 2001-06-18
CN1377365A (zh) 2002-10-30
IL144764A (en) 2007-08-19
CN1152886C (zh) 2004-06-09
KR100607923B1 (ko) 2006-08-04
HK1050536A1 (en) 2003-06-27
CN1557833A (zh) 2004-12-29
EP1177204A2 (en) 2002-02-06
AU784946B2 (en) 2006-08-03
CA2362669A1 (en) 2001-06-14
KR20010112261A (ko) 2001-12-20
NO20013856L (no) 2001-10-08
HUP0203032A3 (en) 2003-04-28
PE20010917A1 (es) 2001-09-10
CO5280211A1 (es) 2003-05-30
MY131878A (en) 2007-09-28
EA200100871A1 (ru) 2002-04-25
NZ513961A (en) 2004-02-27
BR0008057A (pt) 2002-04-23
JP2003516414A (ja) 2003-05-13
IL176511A (en) 2007-08-19
EA007934B1 (ru) 2007-02-27
WO2001042272A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
ZA200200741B (en) Oral liquid compositions.
MXPA01010676A (es) Composicion farmaceutica de vitamina d o un analogo de vitamina d y al menos un corticoesteroide.
GB9909020D0 (en) Time estimator
GB0016698D0 (en) Tie
ZA200110413B (en) Crystalline 1-methylcarbapenem compounds.
MXPA01008056A (es) Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada.
ZA200000857B (en) Pharmaceutical composition.
GB2356092B (en) Delay line
IL144455A0 (en) 16-hydroxyestratrienes as selective estrogens
HUP0201795A3 (en) Disinfectants
IL144757A0 (en) Eplerenone crystalline form
MXPA00007601A (es) Cronometro.
AU141195S (en) Shear
PH12001001922B1 (en) Crystalline therapeutic agent.
AU5092001A (en) Crystalline pharmaceutical
ZA200107145B (en) Eplerenone crystalline form exhibiting enhanced dissolution rate.
EP1204445A4 (en) CRYSTALLIZATION MACHINE
HU0003380D0 (en) Reversible plough
GB2353580B (en) Blockage buster
CA89270S (en) Tie
GB9910326D0 (en) Ploughs
GB0001176D0 (en) Tie
GB9925372D0 (en) Tie
GB9914843D0 (en) Perforation
ZA991824B (en) Towel.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal